TherapeuticsMD (TXMD) Net Cash Flow (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Net Cash Flow came in at $944000.0 in Q1 2026, up 35.05% YoY from $699000.0 in Q1 2025, and up 151.73% on a QoQ basis from $375000.0 in Q4 2025.
TherapeuticsMD (TXMD) Net Cash Flow (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 17 years of Net Cash Flow data on file, last reported at $944000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 35.05% year-over-year to $944000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 28.65% YoY) and the FY2025 annual result came in at $2.5 million, up 109.74% from the prior year.
- Net Cash Flow improved to $944000.0 in Q1 2026, from $375000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $19.5 million in Q3 2022 to a low of -$140.8 million in Q2 2022.
- A 5-year average of -$14.3 million and a median of -$71000.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 437.54% — and 2025, when it surged 2105.88%.
- Tracing TXMD's Net Cash Flow over 5 years: stood at -$81.8 million in 2022, then jumped by 96.38% to -$3.0 million in 2023, then soared by 100.57% to $17000.0 in 2024, then surged by 2105.88% to $375000.0 in 2025, then jumped by 151.73% to $944000.0 in 2026.
- The last three Net Cash Flow figures came in at $944000.0 (Q1 2026), $375000.0 (Q4 2025), and $999000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 779,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 779,000.00 |
| Jun 30, 2026 | 779,000.00 |
| Mar 31, 2026 | 944,000.00 |
| Mar 31, 2026 | 944,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Sep 30, 2025 | 999,000.00 |
| Sep 30, 2025 | 999,000.00 |
| Jun 30, 2025 | 381,000.00 |
| Jun 30, 2025 | 381,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Sep 30, 2024 | -71,000.00 |
| Sep 30, 2024 | -71,000.00 |
| Jun 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | -229,000.00 |
| Mar 31, 2024 | -229,000.00 |